Oji
Daeseok Oji, Gumi-Si KR
Patent application number | Description | Published |
---|---|---|
20110134103 | LIQUID CRYSTAL DISPLAY - A liquid crystal display includes according to an embodiment a display panel provided with a plurality of data lines, a plurality of gate lines intersecting the data lines, liquid crystal cells arranged in a matrix, and TFTs disposed at the intersections of the data lines and the gate lines; source drive ICs configured to supply data voltages to the data lines, wherein polarities of data voltages are reversed by a column inversion scheme; and a gate driver configured to sequentially supply gate pulses for the gate lines, wherein polarities of the data voltages charged in the liquid crystal cells in the display panel are reversed in dot unit. | 06-09-2011 |
Hiroshi Oji, Shizuoka JP
Patent application number | Description | Published |
---|---|---|
20080230842 | Semiconductor Device Having High-K Gate Dielectric Layer and Method For Manufacturing the Same - A semiconductor device having a high-K gate dielectric layer includes a p-type well that is formed in an upper layer of a silicon substrate. Arsenic ions are implanted into an extreme surface layer of the p-type well and a heat treatment is performed to form a p-type low-concentration layer. A HfAlOx film and a polycrystalline silicon layer are laminated on the substrate. A gate electrode is formed by patterning the polycrystalline silicon layer. After a n-type extension region is formed by implanting arsenic ions by using the gate electrode as a mask, sidewall spacers are formed on sides of the gate electrode. Arsenic ions are implanted by using the sidewall spacers and the gate electrode as masks, whereby n-type source/drain regions are formed. | 09-25-2008 |
Hiroshi Oji, Kyoto JP
Patent application number | Description | Published |
---|---|---|
20090011555 | Method of manufacturing CMOS integrated circuit - In a method of manufacturing a CMOS integrated circuit according to the present invention, a PSD step (step of forming P-type source/drain regions) is first carried out, and an NSD step (step of forming N-type source/drain regions) is thereafter carried out, in order to create a mixed structure of a silicide transistor and a non-silicide transistor. Thus, a step of depositing an oxide film on a substrate surface may be carried out only once, the oxide film can be removed by a single step of etching with hydrofluoric acid, and the operating characteristics of formed devices can be excellently maintained. | 01-08-2009 |
20110037127 | CMOS INTEGRATED CIRCUIT - A MOS integrated circuit including an N-type silicide MOS transistor, an N-type non-silicide MOS transistor simultaneously formed with the N-type silicide MOS transistor, and an isolation film having an N conductivity type impurity formed on the N-type non-silicide MOS transistor. | 02-17-2011 |
Hiroshi Oji, Hamamatsu-Shi JP
Patent application number | Description | Published |
---|---|---|
20090057739 | Ge channel device and method for fabricating ge channel device - The Ge channel device comprises: a Ge channel layer ( | 03-05-2009 |
Naoto Oji, Tokyo JP
Patent application number | Description | Published |
---|---|---|
20130027160 | SINTERED MAGNET AND METHOD FOR PRODUCING THE SINTERED MAGNET - The present invention aims to ensure strength of a thin-walled sintered magnet. A sintered magnet is a ferrite sintered magnet made by sintering a magnetic material. A magnetic powder mixture obtained by mixing magnetic powder with a binder resin is injection-molded into a mold with a magnetic field applied thereto to produce a molded body, which is then sintered to produce the sintered magnet. The sintered magnet has a thickness of 3.5 mm or less in the position of center of gravity thereof. The sintered magnet has a surface roughness Rz of 0.1 or more and 2.5 μm or less. The surface roughness Rz is a 10 point average roughness. | 01-31-2013 |
Nneka Amarachi Dawn Oji, Kansas City, MO US
Patent application number | Description | Published |
---|---|---|
20130173278 | MANAGING UPDATES FROM REFERENCE LABORATORIES - Computerized systems, methods, and graphical user interfaces are provided to facilitate communication between physician offices and reference laboratories. A reference laboratory content manager provides a centralized conduit for interfacing clients placing orders for reference laboratory testing and reference laboratories performing testing. The reference laboratory content manager leverages centralized mapping across organizations by managing associations for procedures between reference laboratory aliases and client aliases. The centralized mapping enables the reference laboratory content manager to manage updates from reference laboratories and facilitate clients wishing to modify utilization of reference laboratories. | 07-04-2013 |
20130173289 | FACILITATING MODIFYING REFERENCE LABORATORIES - Computerized systems, methods, and graphical user interfaces are provided to facilitate communication between physician offices and reference laboratories. A reference laboratory content manager provides a centralized conduit for interfacing clients placing orders for reference laboratory testing and reference laboratories performing testing. The reference laboratory content manager leverages centralized mapping across organizations by managing associations for procedures between reference laboratory aliases and client aliases. The centralized mapping enables the reference laboratory content manager to manage updates from reference laboratories and facilitate clients wishing to modify utilization of reference laboratories. | 07-04-2013 |
20130173290 | LEVERAGING CENTRALIZED MAPPING BETWEEN ORGANIZATIONS - Computerized systems, methods, and graphical user interfaces are provided to facilitate communication between physician offices and reference laboratories. A reference laboratory content manager provides a centralized conduit for interfacing clients placing orders for reference laboratory testing and reference laboratories performing testing. The reference laboratory content manager leverages centralized mapping across organizations by managing associations for procedures between reference laboratory aliases and client aliases. The centralized mapping enables the reference laboratory content manager to manage updates from reference laboratories and facilitate clients wishing to modify utilization of reference laboratories. | 07-04-2013 |
Takuya Oji, Kobe-Shi JP
Patent application number | Description | Published |
---|---|---|
20130192731 | PNEUMATIC TIRE - A tread portion of a pneumatic ti re includes inner land portions between outer circumferential main grooves disposed most on tread ground-contact end sides and at least one inner circumferential main groove on the inner side thereof. The inner land portions are divided into inner blocks by inner lateral grooves inclined at an angle α of 10 to 40°. The inner lateral grooves consist of first inner lateral grooves and second inner lateral grooves which are alternately arranged in a circumferential direction. The first inner lateral grooves include a wide-width part connecting to the outer circumferential main groove and a narrow-width part connecting to the inner circumferential main groove. | 08-01-2013 |
20160089939 | PNEUMATIC TIRE - A pneumatic tire includes a tread portion provided with a circumferentially and continuously extending zigzag shoulder main groove located adjacent to a tread edge, a shoulder lateral groove extending axially outwardly from the shoulder main groove and a central lateral groove extending axially inwardly from the shoulder main groove. The shoulder main groove includes an inner corner portion protruding axially inwardly. The central lateral groove includes a first groove portion, a second groove portion and a confluence portion at which the first groove portion and the second groove portion meet. The confluence portion of the central lateral groove is communicated with the inner corner portion of the shoulder main groove. The shoulder lateral groove is located so that an extended portion in which the shoulder lateral groove is extended axially inwardly overlaps with the confluence portion at least partially. | 03-31-2016 |
Yoshihiro Oji, Chita-Gun JP
Patent application number | Description | Published |
---|---|---|
20150276031 | ROTATION AND STOP RETENTION SWITCHING APPARATUS - A rotation and stop retention switching apparatus includes a rotary member being rotary driven, a slider being movable in an axial direction of a rotary axis of the rotary member, a transmission member transmitting a rotary force of the rotary member to the slider, a biasing member biasing the slider in the axial direction of the rotary axis, and a stopper member coming in contact with the slider being biased by the biasing member. The rotary force of the rotary member is transmitted to the slider via the transmission member in a state where the slider is disengaged from the stopper member by a movement of the slider in the axial direction of the rotary axis, the movement caused by the translational force of the slider with a use of the transmission member against a biasing force of the biasing member. | 10-01-2015 |
Yusuke Oji, Toyonaka-Shi, Osaka JP
Patent application number | Description | Published |
---|---|---|
20160084841 | Method for Predicting Clinical Effect of Immunotherapy - Provided is a method for predicting a clinical effect on a subject in a WT1 peptide immunotherapy, said method comprising: a) a step for contacting a sample derived from the subject with WT1 antigen peptide or a variant thereof; and b) a step for detecting the binding of the sample to the WT1 antigen peptide or a variant thereof and thus measuring anti-WT1 antigen peptide IgG antibody titer existing in the sample, characterized in that an increase in the anti-WT1 antigen peptide IgG antibody titer in the subject determines the achievement of a favorable clinical effect. Also provided is a kit for performing the method according to the present invention, said kit containing WT1 antigen peptide or a variant thereof. | 03-24-2016 |
Yusuke Oji, Suita-Shi JP
Patent application number | Description | Published |
---|---|---|
20110190384 | siRNA Specific to WT1 17AA(-)Isoform and Use Thereof - Disclosed is a polynucleotide having at least 15 contiguous bases in the base sequence of SEQ ID NO:26 and including the base sequence of SEQ ID NO:27. Also disclosed is siRNA produced based on the polynucleotide. By means of this, a cancer cell-specific molecular-targeted therapy, which successfully controls the function of WT1, can be realized. | 08-04-2011 |
Yusuke Oji, Osaka JP
Patent application number | Description | Published |
---|---|---|
20120021994 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 01-26-2012 |
20130115696 | siRNA that Inhibits WT1 Gene Expression and Uses Thereof - The present inventors discovered that siRNAs targeting the 17AA site of the WT1 gene not only suppress the expression of the WT1 gene, but also demonstrate remarkable cell growth-suppressing effects and cell death-inducing effects in cancer cell lines. | 05-09-2013 |
20150361147 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 12-17-2015 |
20160051652 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 02-25-2016 |